Poolbeg makes promising progress with RSV programme

Poolbeg Pharma revealed promising results from the lab-based analysis and prioritisation of respiratory syncytial virus (RSV) drug targets and treatments on Wednesday, driven by its artificial intelligence (AI) programme.

The AIM-traded firm said a team of scientific experts had assessed the extensive data collected during the lab-based analysis, prioritising a select group of RSV drug candidates.

It was now actively exploring the most efficient path to advance the prioritised drug candidates to create value.

Poolbeg Pharma said it was confident that the data obtained underscored the potential of its AI-driven programme, bolstering its collaborative endeavours.

The board said global interest in AI-led drug discovery was rising, with major pharmaceutical companies investing significantly.

Poolbeg's RSV AI programme identified drug treatment candidates within a 10-month timeframe.

It said leveraging AI in drug discovery would accelerate timelines, reduce costs, lower risks, and enhance the probability of successfully introducing groundbreaking therapies to patients.

"The positive outputs from this analysis, and the successful prioritisation of our RSV drug candidates, is a testament to the power of our AI-led drug discovery programme," said chief executive officer Jeremy Skillington.

"As we engage in partnering discussions, these results position Poolbeg as a key player in the evolving landscape of AI-driven drug discovery."

At 1224 GMT, shares in Poolbeg Pharma were up 2.43% at 9.27p.

Reporting by Josh White for Sharecast.com.